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Abstract
Background Limited evidence suggests that female breast
tissue ages faster than other parts of the body according to
an epigenetic biomarker of aging known as the ‘‘epigenetic
clock.’’ However, it is unknown whether breast tissue
samples from healthy women show a similar accelerated
aging effect relative to other tissues, and what could drive
this acceleration. The goal of this study is to validate our
initial finding of advanced DNA methylation (DNAm) age
in breast tissue, by directly comparing it to that of
peripheral blood tissue from the same individuals, and to
do a preliminary assessment of hormonal factors that could
explain the difference.
Methods We utilized n = 80 breast and 80 matching blood
tissue samples collected from 40 healthy female partici-
pants of the Susan G. Komen Tissue Bank at the Indiana
University Simon Cancer Center who donated these sam-
ples at two time points spaced at least a year apart. DNA
methylation levels (Illumina 450K platform) were used to
estimate the DNAm age.
Results DNAm age was highly correlated with chrono-
logical age in both peripheral blood (r = 0.94, p\ 0.0001)
and breast tissues (r = 0.86, p\ 0.0001). A measure of
epigenetic age acceleration (age-adjusted DNAm Age) was
substantially increased in breast relative to peripheral blood
tissue (p = 1.6 9 10-11). The difference between DNAm
age of breast and blood decreased with advancing
chronologic age (r = -0.53, p = 4.4 9 10-4).
Conclusions Our data clearly demonstrate that female
breast tissue has a higher epigenetic age than blood col-
lected from the same subject. We also observe that the
degree of elevation in breast diminishes with advancing
age. Future larger studies will be needed to examine
associations between epigenetic age acceleration and
cumulative hormone exposure.
Keywords Breast cancer  Tissue aging  DNA
methylation  Epigenetics  Biomarker of aging  Estrogen 
Cell cycling
Introduction
We recently developed a multi-tissue age estimator (re-
ferred to as epigenetic clock) that accurately estimates
chronological age across multiple cells and tissues based
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on DNA methylation data [1]. The resulting age estimate is
referred to as ‘‘epigenetic age’’ or ‘‘DNA methylation age.’’
An increasing body of literature shows that the epigenetic
age estimate captures aspects of the biological age of the
underlying tissue. For example, the epigenetic age of blood
is predictive of all-cause mortality after adjusting for
chronological age and known risk factors of mortality
[2–5]. The epigenetic clock method has shown that certain
tissues exhibit age acceleration due to obesity [6], Alz-
heimer’s disease [7], Down syndrome [8], Parkinson’s
disease [9], HIV [10, 11], Huntington’s disease [12], life-
time stress [13], and menopause [14].
This epigenetic aging measure lends itself to contrasting
the biologic ages of different tissues of the human body
[15]. In an earlier publication, we presented evidence that
female breast tissue may be biologically older than other
parts of the body, using data from 82 publicly available
Illumina datasets from many different tissues [1]. However,
the earlier analysis surrounding epigenetic aging effects in
breast tissue had a methodological limitation, which was
that it was mostly based on normal adjacent tissues from
breast cancer patients. The only normal breast tissue
dataset (N = 23) in that study was used in the training data,
and there were two normal adjacent breast tissue datasets
(N = 81 and N = 27) from breast cancer patients from
TCGA used in the test data. Since cancer field effects and
other hidden biases may have confounded our original
analysis, the purpose of this study was to validate the
accelerated aging effect of female breast tissue using
matched specimens from the breast tissue and peripheral
blood from healthy female volunteers. Further, we aimed to
expand our original analysis by examining longitudinal
changes in epigenetic age in breast compared with blood
using matched samples within subject over time, and
adding a preliminary assessment of the influence of
menopausal status and reproductive factors on the epige-
netic age acceleration in breast and blood tissue.
Methods
Study specimens
This study made use of specimens from the Susan.
G. Komen Tissue Bank (KTB) at the Indiana University
Simon Cancer Center funded by Susan G. Komen Foun-
dation. This is a unique resource developed with the goal of
understanding normal breast biology, to better understand
the disruption that occurs during breast carcinogenesis, and
to accelerate breast cancer prevention research. Partici-
pants in the KTB are healthy tissue donors without a his-
tory of breast cancer.
We requested samples from a subset of healthy female
donors who had provided both peripheral blood and breast
tissue at two time points spaced at least a year apart,
focusing on groups selected for parity and menopausal
status: (1) pre-menopausal and nulliparous, (2) pre-meno-
pausal with C1 live birth, (3) post-menopausal and nulli-
parous, and (4) post-menopausal with C1 live birth. Study
specimens were anonymized, with detailed risk annotation.
Samples for our study were selected based on whether
the participant had specimens and data available at least
two visits, spaced at least 1 year apart. When more than
two longitudinal samples were present, we requested all
samples. The time interval between visits was allowed to
vary, provided it was greater than 1 year.
Tissue acquisition and processing
Breast tissue
Six core samples were taken from the upper outer quadrant
of the breast from each donor under local anesthesia.
Within 5 min of procurement, each core was placed into an
embedding cassette, and the cassettes were placed into 10%
buffered formalin and stored at room temperature. The
specimens were then embedded in paraffin. After flash
freezing in liquid nitrogen, frozen cores were placed in
labeled, chilled cryovials, and stored in liquid nitrogen at
-166.2 C. 84 breast tissue samples, with 50 mg of breast
tissue per sample, were shipped to UCLA neurogenetics
core laboratory, where DNA and RNA were extracted
using the AllPrep kit. 38 of 84 samples had low DNA yield
([20 ll at 100 ng/ll) potentially because of increased
percent of fatty tissue and DNA extraction was repeated
using leftover tissue from these specimens, with adequate
yields in all but one case (0.8 lg total). Extracted DNA was
then used for bisulfite sequencing experiments.
Peripheral blood specimens
At the Komen Tissue Bank, blood was drawn into the
blood collection tube (EDTA 9 ml) and gently mixed.
After centrifugation, plasma was withdrawn and the
remaining red cells and buffy coat were stored at -80 C
until DNA extraction. DNA was extracted from the blood
cells at Indiana CTSI Specimen Storage Facility lab using
an AutogenFlex Star (SN 401033) instrument and the
Flexigene AGF3000 blood kit for DNA extractions from
whole fresh and frozen blood. Four 50 ll aliquots of each
sample were pipetted into pre-labeled DNAstable tubes,
and stored at ambient temperature. These DNA samples
were then shipped to the UCLA for bisulfite sequencing
experiments.
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DNA extraction
AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, cat #
80224) was used for the DNA extractions for frozen tissue
samples. 30 mg of frozen tissue was lysed with 600 ul
guanidine-isothiocyanate-containing Buffer RLT Plus in a
2.0 ml micro centrifuge tube, and homogenized using
TissueLyser II (Qiagen) with 5 mm stainless steel beads.
Tissue lysate was continued with the AllPrep protocol for
simultaneous extraction of genomic DNA and total RNA
using RNeasy Mini spin column technology.
DNA methylation data pre-processing
Bisulfite conversion using the Zymo EZ DNA Methylation
Kit (ZymoResearch, Orange, CA, USA) as well as subse-
quent hybridization of the HumanMethylation450k Bead
Chip (Illumina, SanDiego, CA), and scanning (iScan,
Illumina) was performed according to the manufacturer0s
protocols by applying standard settings. DNA methylation
levels (b values) were determined by calculating the ratio
of intensities between methylated (signal A) and un-
methylated (signal B) sites. Specifically, the b value was
calculated from the intensity of the methylated (M corre-
sponding to signal A) and un-methylated (U corresponding
to signal B) sites, as the ratio of fluorescent signals
b = Max(M,0)/[Max(M,0) ? Max(U,0) ? 100]. Thus, b
values range from 0 (completely un-methylated) to 1
(completely methylated).
Laboratory performance
We analyzed 22 sets of duplicate samples (13 peripheral
blood and 9 breasts) in order to examine for concordance.
Blood samples and breast samples were randomized across
the Illumina chip to avoid confounding due to technical
sources of variation.
Statistical methods and analysis
Study variables
Survey data were available on age at tissue donation,
education, ethnicity, age at menarche, menopausal status,
age at menopause, gravidity, parity, duration of breast-
feeding (months), use of oral contraceptives, and hormone
replacement (ever used). We examined the covariate Total
Menstrual Years, which was calculated as the difference
between age at menopause if post-menopausal (replaced by
current age if pre-menopausal) and age at menarche.
Epigenetic biomarker of aging
The epigenetic measure of tissue age is calculated by
combining the DNA methylation levels of 353 dinucleotide
markers known as cytosine phosphate guanines or CpGs
[1]. The weighted average of these 353 epigenetic markers
gives rise to an estimate of tissue age (in units of years),
which is referred to as ‘‘DNA methylation age’’ (DNAm
age) or as ‘‘epigenetic age.’’ This epigenetic clock method
to estimate age applies to any tissue or cell type that
contains DNA (with the exception of sperm) and applies to
all 3 versions of the Illumina methylation array (Infinium
27K, Infinium 450K, and the most recent EPIC array).
Mathematical details and software tutorials for the epige-
netic clock can be found in the Additional files of Horvath
[1]. An online age calculator can be found at our webpage
(https://dnamage.genetics.ucla.edu).
Multivariate analysis
Pearson correlation was examined between DNAm age and
chronologic age in both breast and peripheral blood. We
used multivariate linear regression models in order to
examine relationships between DNAm age and the demo-
graphic and reproductive variables listed above. Because
DNAm age was available at multiple time points for both
breast and peripheral blood, we used linear mixed effects
models to examine the association between longitudinal
changes in DNAm age and the dependent variables listed
above.
CpG islands
To delve more deeply into the difference between breast
and blood tissue, we looked at the effect of chronological
age on the methylation levels of individual CpGs. It is
well known that CpGs islands, regions with a high fre-
quency of CpG sites located at or near the transcription
start site of genes, tend to gain methylation with age,
while those outside of islands tend to lose methylation
levels [16]. We calculated mean methylation at CpGs
within islands for each participant and compared these
values to those located in other chromosomal locations,
with separate analyses for breast and peripheral blood.
Pearson correlation statistic of methylation levels against
age was calculated for breast and peripheral blood. Non-
parametric group comparison tests (Kruskal–Wallis) were
performed to test for mean differences in methylation
between (1) island versus non-island CpGs, and (2) breast
versus peripheral blood groups.
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Results
Comparison of epigenetic clock in breast
and peripheral blood samples from healthy
women donors
We received DNA isolated from peripheral blood and
matched breast tissue samples from 49 healthy women who
donated at two or more time points. 9 of the women in our
sample did not have adequate breast tissue specimens and
our analysis was focused on the remaining 40 women who
had matched peripheral blood and breast samples. Indi-
viduals in our sample were aged 18–65 years, with 22 pre-
menopausal, 18 post-menopausal, 17 nulliparous, and 23
with at least one live birth. We analyzed data from n = 192
breast and peripheral blood samples from 2 or more time
points from 40 individuals. All samples were profiled in a
single batch using the Illumina 450k platform. 24 of these
samples were duplicates (13 peripheral blood, 9 breast).
Analysis of 24 sets of duplicate samples revealed excellent
concordance (correlation coefficient 0.97, p\ 0.0001)
between samples. Blood samples and breast samples were
randomized across the Illumina chip to avoid confounding
due to technical sources of variation.
An overview of our participant population is presented
in Table 1. Chronological age at the time of sample col-
lection ranged from 18 to 65 years (mean age = 42.5) at
the first time point, 21–70 years (mean age = 46.7) at the
second time point, with a mean age difference between the
two assessments of 4.2 years (range 2–7 years) between
the two assessments. There were two individuals who were
pre-menopausal at the first visit and post-menopausal at the
second. There were three individuals who were nulliparous
at the first visit and had at least 1 live birth at the second.
Our sample included 6 Hispanic, 1 African American,
and 1 East Asian woman. Two individuals were Ashkenazi
Jewish. We have previously shown that race/ethnicity has a
weak association with epigenetic age acceleration in blood
tissue [17]. However, race/ethnicity was not associated
with epigenetic age acceleration in this study, which might
reflect the low sample sizes.
As expected, DNAm age has a strong linear relationship
with chronological age in all samples, with the correlation
coefficient being higher for peripheral blood (q = 0.94,
p\ 0.0001 at the baseline visit) than for breast tissue
(q = 0.86, p\ 0.0001) (Fig. 1, panels A–C). Using the
Fisher r-to-z transformation, a z-value of 1.74 was calcu-
lated with a one-tailed p value of 0.04 revealing a signifi-
cant difference between the correlation coefficients of 0.94
and 0.86. To formally measure age acceleration effects, we
defined age acceleration residual for each sample by taking
the residuals from the linear regression of DNAm age on
chronologic age. This measure was significantly higher in
breast compared with blood (Fig. 1d).
When we examine the linear relationship between
DNAm age and chronologic age in breast and blood tissue
separately, we can calculate the distance between these two
regression lines to compare the difference in DNAm age
between breast and blood for varying chronologic ages. For
women aged 21 years, breast appears 17.5 years older than
blood, whereas for women aged 55 years, breast appears
8 years older than blood. The full distribution of tissue
differences of DNAm age between breast and blood is
shown in Fig. 2a. For the majority of participants, breast
was much older than blood. Interestingly, the degree of
separation in DNAm age between breast and blood is
greatest at younger ages, and there is convergence around
the age range that is typically associated with the meno-
pausal transition. The absolute difference in DNAm age
between breast and blood was inversely correlated with
advancing age (r = -0.53, p = 4.4 9 10-4) (Fig. 2b). We
found that the difference between breast and blood was
significantly higher in pre-menopausal women than in post-
menopausal women (p = 0.0098 using the non-parametric
Table 1 Overview of the KTB breast and peripheral blood methylation dataset
Age\ 50 years Age C 50 years Overall
Participants (n) 24 16 40
Age at first donation (mean, SD) 33.8 (8.8) 55.4 (4.3) 42.5 (12.9)
Years between first and second donation (mean, range) 3.9 (2–7) 4.7 (3–6) 4.2 (2–7)
Nulliparous (n) 12 5 17
No.of live births (mean, SD) 0.92 (1.0) 2.0 (1.4) 1.2 (1.2)
No. of pregnancies (mean, SD) 1.0 (1.3) 2.1 (1.5) 1.5 (1.5)
Pre-menopausal (n) 20 2 22
Total menstrual years (mean, range) 20.2 (5–37) 32.6 (13–41) 25.3 (5–41)
Age at menopause (mean, SD) 33.0 (7.2) 45.1 (6.3) 42.5 (8.0)
Participant characteristics for baseline demographic and reproductive variables
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Kruskal–Wallis test) (Fig. 2c). However, in multivariate
analyses, we found that there was not a significant asso-
ciation between difference in DNAm age between breast
and blood and menopausal status (b = 1.1 for pre-meno-
pausal women, p = 0.68) after adjusting for chronologic
age (b = -0.26, p = 0.02).
Longitudinal changes in DNAm age with advancing
chronologic age
Figure 3 shows individual trajectories of DNAm age over
the study interval in both breast tissue and blood. To
examine longitudinal changes in DNAm age over time
between breast tissue and blood, we defined the rate of
change in DNAm age as follows:
Rate of change in DNAm age
¼ ðDNAm age visit 2  DNAm age visit 1ÞðAge visit 2  Age visit 1Þ :
We can examine the full distribution of rate of change in
DNAm age in both breast and blood (Supplementary
Fig. 1a, b). We find that the rate of change in DNAm age is
significantly higher in blood (mean = 0.97) than breast
(mean = 0.61) (p = 0.038 using the non-parametric com-
parison Kruskal–Wallis test) in our sample (Fig. 2d).
While chronological age differences between the first
and second visits ranged from 2 to 7 years (mean 4.2 years,
SD = 1.5), the biologic age difference ranged from -2.6
to 11.7 years (mean 4.1 years, SD = 3.2) as measured by
peripheral blood, and the biologic age difference in breast
tissue ranged from -8.1 to 13.1 years (mean 2.0 years, SD
5.6). It is of note that while 4 peripheral blood samples
demonstrated a younger biologic age at visit 2 than visit 1,
a greater number of breast samples (N = 18) had an esti-
mated DNAm age that was younger at visit 2 than visit 1.
In only one woman, both breast tissue and blood had
estimated younger biologic ages at follow-up compared
with baseline. T-tests comparing the intraindividual dif-
ferences in age between visits 1 and 2 revealed no signif-
icant difference between change in DNAm age of blood
and change in chronologic age across visits (mean change
of 4.1 years vs. 4.2 years p = 0.81), while there was a
significant difference between change in DNAm age of
breast and change in chronologic age across visits (mean
change of 2.0 years vs. 4.2 years, p = 0.025).
Using a linear mixed effects model, we find that the
difference between DNAm age of breast and blood is
associated with chronologic age (b = -0.40, 95% CI
-0.26 to -0.54), and not associated with parity (b = -2.1
for nulliparous women, 95% CI -0.78 to 5.0) or menstrual
status (b = 0.34, 95% CI -3.4 to 4.0). There was a bor-
derline association between the difference between DNAm
age of breast and blood and total menstrual years
(b = 0.16, 95% CI -0.02 to 0.35).
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Fig. 1 Epigenetic clock
analysis of breast tissue and
peripheral blood. a Scatter plot
of DNAm age (y-axis) versus
chronological age (x-axis) for
breast tissue (red) and
peripheral blood (black)
samples at baseline visit,
correlation coefficient = 0.8,
p value = 5.5 9 10-19.
Regression lines demonstrate
the linear relationship between
DNAm age and chronologic age
in all samples (a), in breast
(b, q = 0.86, p value = 1.2 9
10-12) and in blood (c,
q = 0.94, p value = 2.4 9
10-19) separately. d This bar
plot shows the relationship
between epigenetic age
acceleration and tissue type,
using data at baseline visit,
demonstrating the mean value
(y-axis) and one standard error,
with p value = 1.6 9 10-11
from the results from a non-
parametric group comparison
test (Kruskal–Wallis)
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Age effects on individual CpGs differ between breast
and blood
We also studied the effects of chronological age on indi-
vidual CpGs in our dataset. Aging effects were quite dif-
ferent between breast and blood tissue (Fig. 4). In blood,
CpGs that are located in CpG islands tend to have a pos-
itive correlation with chronological age (Fig. 4a). This is a
well-known effect, which has been observed in many other
tissues [16, 18, 19], and is also reflected by a positive
correlation between chronological age and the average
methylation level of island CpGs in blood (q = 0.44,
p = 5.8 9 10-6, Fig. 4c). Surprisingly, this well-known
result from blood cannot be reproduced in breast tissue
(Fig. 4b, d). It is even more surprising that the average
DNA methylation levels of CpGs that are located outside
of CpG islands exhibit a positive correlation with
chronological age in breast tissue (q = 0.24, p = 0.02,
Fig. 4f), which contrasts with the non-significant (negative)
association in blood tissue (Fig. 4e). Overall, these results
suggest that aging effects differ greatly between the two
tissues. We find that the mean methylation levels of CpGs
are lower in breast tissue samples (compared with blood
samples). The effect is particularly significant for CpGs
located outside of CpG islands (p = 6.4 9 10-33, Fig. 4h)
but can even be observed for CpGs located inside of CpG
islands (p = 9 9 10-12, Fig. 4g).
Discussion
To our knowledge, this is the first study to demonstrate that
breast tissue epigenetic age exceeds that of blood tissue in
healthy female donors. In addition to validating our earlier
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Fig. 2 Tissue difference in DNAm age between breast and blood.
a Frequency distribution of the absolute difference DNAm age breast
and DNAm age blood at first visit. On average, DNAm age of breast
is 11.4 years older than that of blood (SD = 7.1, range -7.9 to 23.5
years). b While DNAm age of breast is significantly higher than blood
at younger ages, the gap closes with advancing age. This scatter plot
shows a strong inverse correlation between chronologic age and the
absolute difference DNAm age breast and DNAm age blood
(correlation coefficient = -0.53, p = 4.4 9 10-4), c The absolute
difference between DNAm age breast and DNAm age blood is higher
in pre-menopausal women (mean 13.9, SD 6.3 years) compared with
post-menopausal women (mean 8.3, SD 6.9 years, with
p value = 0.0098 from non-parametric group comparison Kruskal–
Wallis testing). d The rate of change in DNAm age is higher in blood
than breast tissue. This bar plot shows the relationship between rate of
change in DNAm age and tissue type, demonstrating the mean value
(y-axis) and one standard error. While the DNAm age in breast starts
out higher, DNAm age in blood eventually catches up to breast tissue,
with results from a non-parametric group comparison test reveal a
significantly faster rise in DNAm age in blood than breast over time,
with p value = 0.038 (Kruskal–Wallis)
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finding of age elevation in breast tissue, we further
demonstrate that the magnitude of the difference between
epigenetic age of breast and blood is highest in the
youngest women in our study (age 20–30 years) and
gradually diminishes with advancing age. As women
approach the age of the menopausal transition, we found
that the epigenetic of age of blood approaches that of the
breast.
Our studies were performed on whole breast tissue.
Diverse types of cells make up whole breast tissue, with the
majority of cells being adipocytes. Other types of cells
include epithelial cells, cuboidal cells, myoepithelial cells,
fibroblasts, inflammatory cells, vascular endothelial cells,
preadipocytes, and adipose tissue macrophages. This raises
the possibility that the magnitude of the effects we observe,
of breast tissue DNAm age being greater than other tissues,
might be an underestimation, since it is possible that not all
of the cells of the heterogenous sample have experienced
this effect. Since it is difficult to extract DNA from adipose
tissue, we suspect that the majority of DNA extracted from
our whole breast tissues was from epithelial and myoep-
ithelial cells. We hypothesize that the myoepithelial and
epithelial cells in the mammary gland are the cells
responsible for the observed increase in DNAm age,
because these cells are exposed to variability in hormone
levels including estrogen and growth hormone during
puberty, development, and menstrual cycles, and oxytocin
during lactation, with resultant proliferation and cell
cycling. It is of note that across most cell types and tissues
(except breast), there is excellent agreement in estimated
DNAm age from different cells and tissues. Further
experiments are needed to confirm that DNAm age of
isolated breast epithelial and myoepithelial cells is higher
than observed in our study. Furthermore, with advancing
age, the composition of the types of cells within the breast
changes, with increasing proportion of adipose tissue.
Therefore, it is unclear whether the deceleration observed
in our study as a woman approaches menopause is a true
deceleration or whether this observation is a result of loss
of the cell types that experience the deceleration.
We found that the biologic age of peripheral blood was
tightly correlated with chronologic age in the age range
that we studied, consistent with previous studies. The
degree of intraindividual and interindividual variability in
DNAm age of healthy breast tissue had not been previously
quantified. At the baseline visit, the variance in chronologic
age was 167.7, with the variance in biologic age as mea-
sured by DNAm age of the peripheral blood being 161.8,
and breast 92.7. Examining the intraindividual difference
in DNAm age between visits 1 and 2, we note that the
variance of this difference is greater in breast (31.4)
compared with blood (10.4) and chronologic age (2.3).
While we note that a higher proportion of women (18/40)
appeared to have ‘‘younger’’ breasts at follow-up, than the
proportion of women (2/40) who appeared to have
‘‘younger’’ blood at follow-up, there was only one woman
who had both younger blood and breast tissue, suggesting
that this observation may be attributable to the variability
in this measurement. Further studies are needed to examine
whether true reversal of epigenetic aging in breast tissue
ever occurs under any circumstances.
We have observed a strong linear relationship between
DNAm age and chronologic age for both breast and blood
tissue. We infer that a non-linear increase in DNAm age of
breast occurs prior to the adulthood as evidenced by the
higher DNAm age of breast at the youngest adult ages we
have studied. We note that the rate of change in breast
tissue is slower than that of both chronologic age and the
rate of change in peripheral blood. Further studies may
examine for non-linear effects around the age of the
menopausal transition, and for the relationship between
non-linear change in DNAm age and the risk of later
developing breast cancer.
Our findings raise the question of what factors regulate
the aging process in the breast, and whether there are
common mechanisms underlying accelerated aging and
carcinogenesis. We postulate that biologic aging in female
breast tissue may be accelerated beginning at puberty, and
may be linked to stimulation by estrogen, progesterone,
and oxytocin, and cell cycling, so that by early adulthood
the DNAm age in female breast is higher than that of other
blood breast
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tissues, as we observe. Breast cancer overall shows a
bimodal distribution with respect to age, with the first peak
occurring at age 50 years (more commonly medullary or
inflammatory breast cancer), and the second peak reached
at over 70 years of age (more commonly estrogen and
progesterone receptor-positive lobular or mucinous can-
cers) [20]. It is well known that risk of breast cancer is
linked with endogenous estrogen and progesterone expo-
sure, including early menarche, late menopause, nullipar-
ity, age at first birth [21–25], as well as exogenous
exposure to hormone replacement [26]. These relationships
are true in breast cancers diagnosed in pre-menopausal as
well as post-menopausal women [27], and in breast cancers
that are estrogen receptor-positive or negative [28].
Estrogen is known to be involved in the development of the
mammary gland and epithelial stem cell regulation
[29–31]. Estrogen regulates cell cycle progression through
the cyclin-dependent kinase pathway [32]. Proliferation
rates of normal breast epithelial cells as measured by
labeling index studies have shown a decline in proliferation
with advancing age [33–35]. However, the relationship
between estrogen and progesterone stimulation, chronic
cell cycling, and cellular senescence in breast tissue is
poorly understood.
Previous studies have examined the relationship of
hormonal risk factors and the age incidence of breast
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Fig. 4 DNA methylation levels inside and outside of CpG islands.
a Effect of chronological age on CpG methylation versus chromo-
somal location in a blood and b breast tissue. The y-axis of the bar
plot shows the log (base 10)-transformed correlation test p value
(whose sign reflects the sign of the correlation). c, d Mean
methylation levels in CpG islands versus chronological age in
c blood and d breast tissue. e, f Mean methylation levels outside of
CpG islands versus chronological age in e blood and f breast tissue.
g Mean methylation in CpG islands versus tissue type. h Mean
methylation outside of CpG islands versus tissue type
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cancer [35, 36]. Noting the linear log–log relationship
between cancer incidence and age is not observed in breast
cancer compared with most other non-hormone-dependent
cancers, Pike et al. constructed a mathematical model
describing the relationship between cancer incidence and
age that incorporated a decline in the rate of breast tissue
aging starting at age 40 and ending at the last menstrual
period. This modification led to excellent agreement
between observed and predicted effects of age at menarche,
first full-term pregnancy, and menopause on breast cancer
risk. The results of their modeling suggest that hormones
have a major role in determining breast tissue age, and that
the important etiologic elements for breast cancer appear to
be present in pre-menopausal women and sharply reduced
following the menopause [35, 36]. Our finding that epi-
genetic age elevation in adult female breast is highest
following development and gradually diminishes with
advancing age and the menopausal transition is consistent
with the concept that hormonal factors drive breast aging
and the degree of difference between breast and other tis-
sues is reduced with advancing age.
Many reproductive factors may influence changes in
DNAm age of healthy female breast tissue. While our
explorative, hypothesis-generating study reported here was
not powered to answer these important questions, the
Komen Tissue Bank provides a rich resource to examine
the influence of cumulative estrogen exposure on DNAm
age. Future studies are needed to examine overlapping
effects of nulliparity, age at first birth minus age at
menarche, age at menopause, exogenous estrogen expo-
sure, lactation, fertility treatments, and proximity of preg-
nancy to the time of sampling, and whether these factors
modulate DNAm age acceleration. Using large cohort
studies, we have recently shown that early menopause is
associated with accelerated epigenetic age of blood [14].
Our limited sample size did not allow us to test whether a
similar age acceleration effect can also be observed in
breast tissue from post-menopausal women. We hypothe-
size an acceleration in breast tissue epigenetic aging occurs
beginning a puberty, leading to an elevated DNAm age that
persists until menopause. We anticipate that the rate of
epigenetic aging following the menopausal transition may
coincide with the rate of other tissues. Furthermore, with
advancing age, the composition of the types of cells within
the breast changes, with increasing proportion of adipose
tissue. Therefore, it is unclear whether the deceleration
observed in our study as a woman approaches menopause
is a true deceleration or whether this observation is a result
of loss of the cell types that experience the deceleration.
We will direct future studies in healthy women to examine
accelerations in epigenetic aging, cumulative hormone
exposure, and cellular changes in response to pregnancy.
Future studies should also explore epigenetic age
differences in male and female breast tissue, and examine
whether the degree of epigenetic age acceleration is asso-
ciated with increased risk of breast cancer. In the present
study, we confirm that healthy breast tissue exhibits
accelerated aging relative to other tissues, and we have
previously shown that epigenetic age of normal adjacent
breast tissue in breast cancer patients is accelerated. While
the current study does not directly compare methylation
patterns in healthy breast tissue versus normal adjacent
breast tissue in breast cancer patients, future studies are
needed to assess for cancer field effects on epigenetic
aging.
Further analyses will be improved by the addition of
variables related to breast cancer risk, including history of
benign breast disease, and family history. While our study
was not powered to examine these effects, future studies
will include these variables and test whether they are
associated with accelerations in breast epigenetic age. By
extending the Pike model to data from the Nurses’ Health
Study, a large cohort study examining risk factors for major
chronic diseases in women, Rosner and Colditz were able
to show that age at all births, benign breast disease, type of
menopause and use of post-menopausal hormones, and
alcohol use have long-term influence on breast cancer
incidence [37, 38]. Furthermore, recent results reported
using survey data from The Growing Up Today Study, a
large study of girls who are daughters of Nurses’ Health
Study participants, show body size factors from pregnancy
to late adolescence were associated with risk of benign
breast disease [39]. Future work should be directed towards
the important question of whether epigenetic age of the
breast is related to body size, body mass index, and risk of
benign breast disease.
Mammographic breast density is known to be associated
with breast cancer risk [40–42]. A longitudinal cohort
study tracking change in percent mammographic density
over 3–12 years revealed a slowing in the rate of decline,
with annual rates of decline of 1.4, 0.7, and 0.1% at age 50,
57, and 60 years, respectively [43]. Higher body mass
index, greater parity, and younger age at first child’s birth
are associated with lower percent mammographic density,
while more immediate factors such as the use of hormone
therapy and the menopausal transition affect the rate of
change in mammographic breast density [43, 44]. Our work
also motivates the question of whether there may be a link
between epigenetic age and breast density, whether accel-
erated breast epigenetic aging may explain the difference in
biology and risk factors for pre-menopausal and post-
menopausal breast cancer, and whether epigenetic signa-
tures in female breast biopsies may provide additional
information, beyond known risk factors, of breast cancer
risk in a population of women at high risk for breast cancer.
Identifying mechanisms by which age-related changes may
Breast Cancer Res Treat (2017) 164:209–219 217
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contribute to breast cancer development and progression
may aid in the development of a clinical biomarker of
elevated breast cancer risk.
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